Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Axon guidance (mmu04360)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
1500003O
03Rik
KLA  ATP  ATP+KLA
 NM_019769 RIKEN cDNA 1500003O03 gene (1500003O03Rik), mRNA [NM_019769] KLA .92 .89 .89 .86 .85 .92 1.08
ATP 1.01 1.16 1.16 1.53 1.70 3.33 2.09
KLA/ATP .89 .97 .93 1.17 1.19 2.86 2.57
2010110P
09Rik
KLA  ATP  ATP+KLA
 NM_027363 RIKEN cDNA 2010110P09 gene (2010110P09Rik), mRNA [NM_027363] KLA .99 .98 1.02 .99 .94 1.01 1.01
ATP 1.04 1.05 .97 1.05 .95 .98 .95
KLA/ATP .93 1.00 1.02 .97 1.01 .96 .97
Abl1
KLA  ATP  ATP+KLA
 AK083248 adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630031E05 product:v-abl Abelson murine leukemia oncogene 1, full insert sequence. [AK083248] KLA 1.07 1.07 .92 1.01 .98 1.07 .98
ATP .98 .99 .94 .90 .99 1.07 1.04
KLA/ATP 1.04 1.01 1.03 .98 .97 .95 .99
Abl1
KLA  ATP  ATP+KLA
 NM_009594 c-abl oncogene 1, receptor tyrosine kinase (Abl1), transcript variant 2, mRNA [NM_009594] KLA .63 .62 .65 .71 .96 1.17 1.05
ATP 1.01 1.16 1.03 1.14 1.12 .98 .98
KLA/ATP .66 .64 .67 .73 .84 .90 1.05
Ablim1
KLA  ATP  ATP+KLA
 AF316037 actin-binding double zinc finger protein mRNA, 3 untranslated region, partial sequence. [AF316037] KLA 1.07 1.00 .95 1.03 1.02 1.04 1.05
ATP .95 .94 .99 .98 .98 .96 1.04
KLA/ATP .99 .99 .96 1.04 1.03 1.01 .83
Ablim1
KLA  ATP  ATP+KLA
 BC032216 actin-binding LIM protein 1, mRNA (cDNA clone IMAGE:5323557), complete cds. [BC032216] KLA .90 .95 1.00 .97 1.02 .98 1.01
ATP .95 1.00 1.07 1.01 .96 1.04 1.03
KLA/ATP .98 1.05 1.02 1.03 1.02 1.09 .93
Ablim1
KLA  ATP  ATP+KLA
 NM_178688 actin-binding LIM protein 1 (Ablim1), transcript variant 1, mRNA [NM_178688] KLA 1.00 1.03 1.02 1.02 .98 .97 .95
ATP 1.00 1.02 .95 .96 1.00 .98 .99
KLA/ATP 1.00 .98 .98 .96 1.00 .97 1.02
Ablim2
KLA  ATP  ATP+KLA
 NM_177678 actin-binding LIM protein 2 (Ablim2), mRNA [NM_177678] KLA 1.10 1.01 1.00 1.02 1.04 1.08 1.02
ATP .99 1.04 1.13 1.18 .96 1.00 .97
KLA/ATP .99 1.04 1.16 1.28 1.08 .92 .96
Ablim3
KLA  ATP  ATP+KLA
 NM_198649 actin binding LIM protein family, member 3 (Ablim3), mRNA [NM_198649] KLA 1.02 1.05 1.03 1.05 1.08 1.07 1.07
ATP .96 1.01 1.04 1.06 1.03 1.00 1.08
KLA/ATP 1.02 .96 .95 1.05 1.06 1.04 1.03
AK036998
KLA  ATP  ATP+KLA
 AK036998 adult female vagina cDNA, RIKEN full-length enriched library, clone:9930034M05 product:unclassifiable, full insert sequence. [AK036998] KLA 1.43 1.09 .89 .79 .96 .97 .71
ATP 1.04 1.04 .71 .64 .90 .82 .82
KLA/ATP 1.34 1.23 1.01 .89 1.10 .82 .75
AK088985
KLA  ATP  ATP+KLA
 AK088985 2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430034J06 product:unclassifiable, full insert sequence. [AK088985] KLA .99 1.07 .92 .88 .96 1.02 .91
ATP 1.03 .86 .92 .85 1.13 1.00 .93
KLA/ATP .95 1.08 .97 .85 .83 .96 .89
Arhgef12
KLA  ATP  ATP+KLA
 NM_027144 Rho guanine nucleotide exchange factor (GEF) 12 (Arhgef12), mRNA [NM_027144] KLA 1.01 .94 .89 .87 .84 .81 .80
ATP 1.05 .94 1.09 .77 .60 .86 .78
KLA/ATP .93 .88 .86 .70 .52 .66 .58
BB113440
KLA  ATP  ATP+KLA
 BB113440 gb|BB113440 RIKEN full-length enriched, adult male urinary bladder Mus musculus cDNA clone 9530041B19 3. [BB113440] KLA .94 .95 .94 .95 1.05 .99 1.05
ATP 1.03 1.07 1.79 1.71 1.51 1.12 1.06
KLA/ATP .95 1.11 1.27 1.15 1.05 1.14 1.25
BC024984
KLA  ATP  ATP+KLA
 BC024984 cDNA clone IMAGE:5028619, partial cds [BC024984] KLA .98 .97 1.02 .96 .99 .95 1.04
ATP 1.05 1.05 .95 .98 1.00 .94 .96
KLA/ATP 1.10 1.05 .95 1.04 1.02 1.00 1.00
Cdc42
KLA  ATP  ATP+KLA
 NM_009861 cell division cycle 42 homolog (S. cerevisiae) (Cdc42), mRNA [NM_009861] KLA 1.04 1.01 1.02 1.04 1.12 1.21 1.12
ATP 1.07 1.10 1.04 1.06 1.02 .95 1.14
KLA/ATP .94 1.04 1.01 .97 .95 1.02 1.25
Cdk5
KLA  ATP  ATP+KLA
 NM_007668 cyclin-dependent kinase 5 (Cdk5), mRNA [NM_007668] KLA .98 .98 .94 1.01 .98 .94 1.16
ATP 1.19 1.35 .97 1.37 .88 .57 1.26
KLA/ATP 1.02 1.10 .80 1.31 .74 .54 1.43
Cfl1
KLA  ATP  ATP+KLA
 NM_007687 cofilin 1, non-muscle (Cfl1), mRNA [NM_007687] KLA .90 1.01 1.14 .87 1.17 1.17 1.48
ATP 1.24 1.60 .81 1.77 1.07 .88 1.27
KLA/ATP 1.33 1.48 .50 1.58 .71 .93 1.31
Cfl2
KLA  ATP  ATP+KLA
 NM_007688 cofilin 2, muscle (Cfl2), mRNA [NM_007688] KLA .62 .65 .74 .97 .99 .97 1.03
ATP .57 .49 .50 .49 .94 .97 .76
KLA/ATP .47 .41 .44 .58 1.02 1.05 .93
Cxcl12
KLA  ATP  ATP+KLA
 NM_001012477 chemokine (C-X-C motif) ligand 12 (Cxcl12), transcript variant 3, mRNA [NM_001012477] KLA .91 .91 .92 .92 .91 1.00 .85
ATP 1.00 .99 1.02 .99 .91 .93 .88
KLA/ATP .89 .91 .97 .97 .94 .93 .82
Cxcl12
KLA  ATP  ATP+KLA
 NM_021704 chemokine (C-X-C motif) ligand 12 (Cxcl12), transcript variant 1, mRNA [NM_021704] KLA 1.01 .96 1.04 1.04 .94 .98 .94
ATP 1.01 .92 .98 1.04 1.02 .94 .98
KLA/ATP 1.02 .98 1.07 .95 1.02 .98 .99
Cxcr4
KLA  ATP  ATP+KLA
 NM_009911 chemokine (C-X-C motif) receptor 4 (Cxcr4), mRNA [NM_009911] KLA .30 .34 .26 .31 .25 .29 .42
ATP 1.27 2.70 6.37 11.61 7.04 1.14 4.92
KLA/ATP .28 .34 .56 2.60 3.47 1.23 1.28
Dcc
KLA  ATP  ATP+KLA
 X85788 gb|M.musculus mRNA for DCC tumour suppressor. [X85788] KLA 1.01 1.04 .94 1.03 .98 1.05 1.02
ATP 1.04 1.04 1.08 1.03 .99 1.05 1.04
KLA/ATP 1.01 1.01 .98 1.05 1.00 .86 .97
Dpysl2
KLA  ATP  ATP+KLA
 NM_009955 dihydropyrimidinase-like 2 (Dpysl2), mRNA [NM_009955] KLA 1.17 1.12 1.17 1.50 1.49 1.74 1.09
ATP 1.03 1.02 1.34 1.54 1.19 .85 .96
KLA/ATP 1.14 1.22 1.55 1.87 1.47 1.28 1.13
Dpysl5
KLA  ATP  ATP+KLA
 NM_023047 dihydropyrimidinase-like 5 (Dpysl5), mRNA [NM_023047] KLA 1.04 .98 .96 1.00 1.00 1.01 1.02
ATP .97 .96 1.00 1.03 1.01 .98 .99
KLA/ATP 1.00 .94 1.04 .91 1.02 .99 1.03
Efna1
KLA  ATP  ATP+KLA
 NM_010107 ephrin A1 (Efna1), mRNA [NM_010107] KLA 1.04 .94 .87 .95 .96 .92 .89
ATP 1.01 1.04 .99 .93 .90 1.05 .94
KLA/ATP .84 .93 .99 .91 .91 .86 .90
Efna2
KLA  ATP  ATP+KLA
 NM_007909 ephrin A2 (Efna2), mRNA [NM_007909] KLA 2.64 2.43 2.68 2.06 1.56 1.06 .92
ATP 1.00 1.20 1.11 1.12 1.04 1.08 .94
KLA/ATP 2.21 2.52 2.57 2.28 1.62 1.40 1.15
Efna3
KLA  ATP  ATP+KLA
 AK020438 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430025D14 product:ephrin A3, full insert sequence. [AK020438] KLA .99 .98 .97 .96 .94 .98 .95
ATP .98 1.05 .98 .96 1.00 1.00 1.02
KLA/ATP 1.01 1.03 1.04 1.03 .99 1.04 .98
Efna4
KLA  ATP  ATP+KLA
 NM_007910 ephrin A4 (Efna4), mRNA [NM_007910] KLA 1.01 .99 1.01 1.01 1.05 1.07 1.02
ATP .99 .98 .98 1.04 .98 .99 1.01
KLA/ATP .97 1.00 1.06 .97 .86 1.04 1.02
Efna5
KLA  ATP  ATP+KLA
 NM_010109 ephrin A5 (Efna5), transcript variant 2, mRNA [NM_010109] KLA 1.04 1.09 1.05 .98 .96 1.02 .97
ATP .92 1.02 1.07 .99 1.00 1.09 1.04
KLA/ATP .95 .93 1.02 1.00 1.04 1.00 1.01
Efna5
KLA  ATP  ATP+KLA
 NM_207654 ephrin A5 (Efna5), transcript variant 1, mRNA [NM_207654] KLA .96 .99 1.07 1.05 1.04 1.06 1.10
ATP .97 .90 1.05 1.03 1.02 1.00 1.04
KLA/ATP 1.07 1.02 1.08 1.03 1.05 1.14 1.01
Efnb1
KLA  ATP  ATP+KLA
 NM_010110 ephrin B1 (Efnb1), mRNA [NM_010110] KLA 1.12 1.04 .91 .96 .65 .80 .89
ATP .91 .87 .73 .68 .59 1.31 1.23
KLA/ATP .96 1.07 .97 .93 .81 1.12 .84
Efnb2
KLA  ATP  ATP+KLA
 NM_010111 ephrin B2 (Efnb2), mRNA [NM_010111] KLA 1.07 1.12 1.07 1.07 1.04 1.01 1.05
ATP 1.01 1.09 1.22 3.27 3.49 2.79 1.15
KLA/ATP 1.07 1.12 1.15 2.82 3.14 2.43 1.35
Efnb3
KLA  ATP  ATP+KLA
 NM_007911 ephrin B3 (Efnb3), mRNA [NM_007911] KLA .99 1.01 1.02 .96 .98 1.02 .95
ATP 1.05 1.13 .98 1.72 2.32 1.32 .99
KLA/ATP 1.00 1.03 1.05 2.15 2.90 1.45 1.17
Epha1
KLA  ATP  ATP+KLA
 NM_023580 Eph receptor A1 (Epha1), mRNA [NM_023580] KLA 1.15 1.09 1.05 1.05 1.07 1.06 .96
ATP .95 1.04 1.05 1.00 1.04 1.17 1.04
KLA/ATP 1.04 1.05 1.10 1.00 1.07 .99 1.01
Epha2
KLA  ATP  ATP+KLA
 NM_010139 Eph receptor A2 (Epha2), mRNA [NM_010139] KLA .88 .76 .65 .75 .84 .89 .83
ATP 1.08 1.14 1.35 3.86 2.84 1.93 1.07
KLA/ATP .82 .84 .78 1.59 1.58 1.62 1.15
Epha3
KLA  ATP  ATP+KLA
 AK089119 10 days neonate olfactory brain cDNA, RIKEN full-length enriched library, clone:E530001O06 product:Eph receptor A3, full insert sequence. [AK089119] KLA 1.05 .95 .95 .95 1.02 1.01 1.06
ATP .97 .97 .98 .98 .96 1.03 1.02
KLA/ATP 1.01 1.00 1.08 .93 1.04 1.00 1.13
Epha3
KLA  ATP  ATP+KLA
 NM_010140 Eph receptor A3 (Epha3), mRNA [NM_010140] KLA 1.04 1.03 1.02 1.02 .98 .99 1.00
ATP .99 .99 1.00 1.02 1.03 1.03 .99
KLA/ATP .99 1.04 .95 1.03 .99 1.02 .96
Epha4
KLA  ATP  ATP+KLA
 NM_007936 Eph receptor A4 (Epha4), mRNA [NM_007936] KLA 1.11 1.21 1.22 1.11 1.13 1.15 1.20
ATP 1.01 1.01 1.05 1.15 1.06 1.52 1.04
KLA/ATP 1.15 1.19 1.20 1.27 1.14 1.27 1.00
Epha5
KLA  ATP  ATP+KLA
 AK034289 adult male diencephalon cDNA, RIKEN full-length enriched library, clone:9330174B07 product:Eph receptor A5, full insert sequence. [AK034289] KLA 1.01 .98 .97 .95 .96 .97 1.02
ATP .97 1.06 1.02 1.03 .99 1.01 .97
KLA/ATP 1.05 1.06 1.04 .99 .99 1.02 1.00
Epha5
KLA  ATP  ATP+KLA
 NM_007937 Eph receptor A5 (Epha5), mRNA [NM_007937] KLA 1.02 1.02 .97 1.00 1.01 1.02 1.05
ATP 1.07 .97 1.02 1.05 1.00 .92 1.08
KLA/ATP 1.01 .99 .97 1.06 .97 1.08 1.02
Epha6
KLA  ATP  ATP+KLA
 NM_007938 Eph receptor A6 (Epha6), mRNA [NM_007938] KLA 1.10 .90 1.01 1.07 1.00 1.00 1.08
ATP .97 .95 1.00 1.06 .94 1.03 1.03
KLA/ATP 1.03 .99 .95 1.00 1.03 1.01 1.03
Epha6
KLA  ATP  ATP+KLA
 U58332 receptor tyrosine kinase mRNA, complete cds. [U58332] KLA 1.00 .94 .99 1.08 .99 1.00 1.06
ATP 1.00 .99 1.04 1.06 .96 1.06 .95
KLA/ATP 1.03 .99 1.01 1.02 .96 .90 .79
Epha7
KLA  ATP  ATP+KLA
 NM_001122889 Eph receptor A7 (Epha7), transcript variant 2, mRNA [NM_001122889] KLA .99 1.02 1.00 .98 1.01 1.07 1.02
ATP .92 .97 .97 .98 1.02 .95 .94
KLA/ATP .97 1.04 1.05 1.04 1.03 1.01 1.13
Epha7
KLA  ATP  ATP+KLA
 NM_010141 Eph receptor A7 (Epha7), transcript variant 1, mRNA [NM_010141] KLA 1.01 1.14 1.03 1.09 1.08 1.04 1.14
ATP .97 1.00 1.06 1.13 1.32 1.48 1.14
KLA/ATP 1.07 1.09 1.10 1.12 1.19 1.33 1.40
Epha8
KLA  ATP  ATP+KLA
 NM_007939 Eph receptor A8 (Epha8), mRNA [NM_007939] KLA 1.04 .92 1.00 1.05 1.02 1.02 .99
ATP .97 1.02 .99 1.02 1.06 .98 1.00
KLA/ATP 1.05 .97 .99 1.02 1.00 1.04 1.03
Ephb1
KLA  ATP  ATP+KLA
 NM_173447 Eph receptor B1 (Ephb1), mRNA [NM_173447] KLA 1.05 .93 .93 1.01 1.03 1.07 .96
ATP .99 1.08 .99 .94 .97 1.08 1.09
KLA/ATP .97 .94 1.08 .96 .95 1.01 .95
Ephb2
KLA  ATP  ATP+KLA
 NM_010142 Eph receptor B2 (Ephb2), mRNA [NM_010142] KLA .99 .96 1.02 1.04 .95 .90 .95
ATP .99 .99 1.02 1.00 .99 .87 .93
KLA/ATP .99 .97 .97 .99 .95 .96 .95
Ephb3
KLA  ATP  ATP+KLA
 NM_010143 Eph receptor B3 (Ephb3), mRNA [NM_010143] KLA .95 .94 .89 .91 .93 .96 .92
ATP .95 1.04 .93 .89 1.30 1.63 1.46
KLA/ATP .87 .96 .98 .94 .95 1.24 1.21
Ephb4
KLA  ATP  ATP+KLA
 L25761 protein-tyrosine kinase mRNA, partial cds. [L25761] KLA .95 .97 .93 .96 .97 .99 .96
ATP .92 .95 1.03 1.02 .99 1.00 1.02
KLA/ATP .89 .94 .90 .97 1.01 .89 .95
Ephb4
KLA  ATP  ATP+KLA
 NM_010144 Eph receptor B4 (Ephb4), mRNA [NM_010144] KLA .97 1.03 .96 .98 .96 .94 .98
ATP .95 .99 1.06 .99 .99 .95 .94
KLA/ATP 1.00 .99 .99 1.00 .95 1.08 .97
Ephb6
KLA  ATP  ATP+KLA
 NM_007680 Eph receptor B6 (Ephb6), mRNA [NM_007680] KLA .88 .80 .82 .85 .74 .71 .64
ATP .98 1.00 .84 .82 .76 .75 .67
KLA/ATP .83 .81 .81 .77 .74 .72 .58
Fes
KLA  ATP  ATP+KLA
 NM_010194 feline sarcoma oncogene (Fes), mRNA [NM_010194] KLA .71 .71 .82 .92 1.13 1.11 .92
ATP .99 .96 .97 .99 .85 .70 1.07
KLA/ATP .71 .68 .70 .84 1.05 .84 1.04
Fyn
KLA  ATP  ATP+KLA
 U70324 Fyn(T) (L-fyn(T)) mRNA, complete cds. [U70324] KLA 1.23 1.27 1.31 1.27 1.31 .87 .48
ATP .88 .71 .66 .75 .90 1.28 .51
KLA/ATP 1.12 1.01 .94 .84 1.25 1.51 .53
Gnai1
KLA  ATP  ATP+KLA
 NM_010305 guanine nucleotide binding protein (G protein), alpha inhibiting 1 (Gnai1), mRNA [NM_010305] KLA .95 1.01 1.01 1.00 1.09 1.10 1.08
ATP 1.06 1.06 .99 1.15 1.02 .94 .99
KLA/ATP 1.02 1.04 .99 1.16 1.01 1.02 1.13
Gnai2
KLA  ATP  ATP+KLA
 NM_008138 guanine nucleotide binding protein (G protein), alpha inhibiting 2 (Gnai2), mRNA [NM_008138] KLA .74 .79 .82 .74 .91 .97 1.10
ATP 1.07 1.16 .78 1.12 .78 .48 .82
KLA/ATP .91 .81 .53 .80 .60 .68 .87
Gnai3
KLA  ATP  ATP+KLA
 NM_010306 guanine nucleotide binding protein (G protein), alpha inhibiting 3 (Gnai3), mRNA [NM_010306] KLA 1.23 1.24 1.14 1.06 .99 1.15 1.09
ATP .96 .93 .86 .64 1.34 2.02 1.35
KLA/ATP 1.20 1.24 .97 .76 1.21 1.62 1.17
Gsk3b
KLA  ATP  ATP+KLA
 NM_019827 glycogen synthase kinase 3 beta (Gsk3b), mRNA [NM_019827] KLA 1.06 1.03 1.11 1.01 1.26 1.28 1.26
ATP 1.18 1.27 1.15 2.07 2.37 2.32 1.67
KLA/ATP 1.15 1.21 .98 1.50 1.67 2.50 2.99
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Itgb1
KLA  ATP  ATP+KLA
 NM_010578 integrin beta 1 (fibronectin receptor beta) (Itgb1), mRNA [NM_010578] KLA 1.05 1.09 1.13 .92 1.01 .93 .88
ATP 1.14 1.30 .92 1.07 1.04 .83 .70
KLA/ATP 1.26 1.30 .87 1.02 .66 .65 .62
Itgb1
KLA  ATP  ATP+KLA
 U37029 integrin beta1D mRNA, partial cds. [U37029] KLA .93 .95 .96 1.01 .97 1.01 .98
ATP 1.05 .99 .99 1.03 1.03 .97 .94
KLA/ATP .99 .98 1.04 .97 1.02 1.01 .99
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
L1cam
KLA  ATP  ATP+KLA
 NM_008478 L1 cell adhesion molecule (L1cam), mRNA [NM_008478] KLA .96 .96 1.06 .81 .79 .64 .49
ATP 1.15 1.42 .96 1.43 .92 .62 .64
KLA/ATP 1.16 1.14 .74 .99 .66 .58 .54
Limk1
KLA  ATP  ATP+KLA
 NM_010717 LIM-domain containing, protein kinase (Limk1), mRNA [NM_010717] KLA .56 .57 .51 .67 .79 .93 .98
ATP .95 .88 .92 .75 1.01 .86 .88
KLA/ATP .53 .52 .56 .49 .90 .84 .51
Limk2
KLA  ATP  ATP+KLA
 NM_010718 LIM motif-containing protein kinase 2 (Limk2), transcript variant 1, mRNA [NM_010718] KLA .69 .73 .79 .92 1.12 1.18 .97
ATP 1.09 1.05 1.02 .90 .70 .93 1.15
KLA/ATP .78 .76 .77 .69 .71 1.07 1.42
LOC10004
3181
KLA  ATP  ATP+KLA
 XM_001479688 gb|PREDICTED: Mus musculus hypothetical protein LOC100043181 (LOC100043181), mRNA [XM_001479688] KLA 1.01 1.02 1.01 1.02 1.03 1.01 1.01
ATP 1.00 1.04 1.00 1.02 1.00 1.03 1.00
KLA/ATP 1.01 1.00 1.04 1.02 1.02 .98 1.02
Lrrc4
KLA  ATP  ATP+KLA
 NM_138682 leucine rich repeat containing 4 (Lrrc4), mRNA [NM_138682] KLA 2.49 1.96 2.25 3.78 4.57 8.02 5.57
ATP .88 .73 .97 .65 .38 .57 2.88
KLA/ATP 1.91 1.76 1.97 1.38 1.31 2.33 6.93
Lrrc4c
KLA  ATP  ATP+KLA
 NM_178725 leucine rich repeat containing 4C (Lrrc4c), mRNA [NM_178725] KLA 1.03 .99 1.03 .99 .97 .96 1.01
ATP .98 1.03 .95 1.00 .99 .97 1.00
KLA/ATP .97 1.10 1.00 1.04 1.01 .99 .98
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Met
KLA  ATP  ATP+KLA
 NM_008591 met proto-oncogene (Met), mRNA [NM_008591] KLA 3.56 3.71 3.68 3.79 4.24 5.89 6.95
ATP .98 .96 1.16 1.21 3.32 12.98 6.60
KLA/ATP 3.75 3.80 3.58 3.28 3.69 4.27 14.22
Mm.13157
2
KLA  ATP  ATP+KLA
 134949023 Unknown KLA 1.04 1.01 .96 .95 .95 1.00 .99
ATP .98 1.02 .99 1.07 .97 .96 1.00
KLA/ATP .96 .88 .91 1.00 1.02 .98 1.05
Mm.16788
2
KLA  ATP  ATP+KLA
 133778956 Unknown KLA 1.04 .90 .96 1.05 1.02 .98 1.00
ATP .97 1.04 .96 1.03 1.02 1.00 .95
KLA/ATP .95 1.05 1.08 1.00 .91 1.02 .93
Mm.24185
7
KLA  ATP  ATP+KLA
 142347489 Unknown KLA 1.18 1.09 1.27 1.24 1.14 1.18 1.15
ATP 1.10 1.02 1.13 1.16 1.04 1.03 1.11
KLA/ATP 1.17 1.19 1.29 1.21 1.10 1.02 1.19
Mm.27560
0
KLA  ATP  ATP+KLA
 125347784 Unknown KLA .79 .85 .86 .82 .86 1.61 2.44
ATP 1.06 .98 1.31 1.11 .84 .60 1.18
KLA/ATP .81 .74 .95 .89 .94 .74 .93
Mm.27590
9
KLA  ATP  ATP+KLA
 142377065 Unknown KLA .85 .82 .88 .83 .92 1.14 1.02
ATP 1.01 .96 1.06 .88 1.63 2.21 1.37
KLA/ATP .80 .90 .92 .80 1.32 1.71 1.05
Mm.27682
6
KLA  ATP  ATP+KLA
 126513132 Unknown KLA .74 .69 .83 .96 .93 .97 1.21
ATP .71 .66 .60 .75 .88 .90 .79
KLA/ATP .63 .57 .63 .72 .89 .99 .90
Mm.27812
KLA  ATP  ATP+KLA
 84794604 Unknown KLA .95 .99 1.00 1.04 1.07 1.12 1.08
ATP .99 1.02 1.00 1.12 1.05 1.08 1.04
KLA/ATP 1.00 1.00 .96 1.02 1.01 1.06 1.01
Mm.29043
3
KLA  ATP  ATP+KLA
 85861261 Unknown KLA 1.78 1.62 1.59 1.01 .62 .83 1.30
ATP 1.00 .91 1.04 1.74 3.44 4.94 1.71
KLA/ATP 1.81 1.75 1.95 2.12 6.63 7.57 2.59
Mm.33138
9
KLA  ATP  ATP+KLA
 158508469 Unknown KLA .80 .79 .81 .82 .72 .64 .50
ATP .95 .85 .56 .48 .30 .33 .46
KLA/ATP .71 .64 .50 .41 .33 .32 .42
Mm.40074
7
KLA  ATP  ATP+KLA
 86788142 Unknown KLA 1.07 1.10 .96 1.05 1.07 1.10 1.01
ATP .98 1.01 1.03 1.06 1.10 1.52 .92
KLA/ATP 1.09 1.06 1.04 1.18 1.09 1.08 .97
Mm.40909
KLA  ATP  ATP+KLA
 67846118 Unknown KLA .97 1.03 1.11 .96 .87 .93 1.00
ATP .99 .94 .98 .99 1.05 .98 .97
KLA/ATP .95 1.01 1.00 1.03 1.06 .97 .97
Mm.47526
5
KLA  ATP  ATP+KLA
 145046272 Unknown KLA 1.05 .97 .80 .91 .84 .88 .82
ATP .96 .81 1.14 .73 .64 1.00 .85
KLA/ATP .91 .89 .98 .66 .67 .78 .64
Mm.5071
KLA  ATP  ATP+KLA
 118130842 Unknown KLA 1.23 1.12 1.19 1.04 .91 .89 .99
ATP .91 1.08 1.08 1.01 1.08 1.64 1.83
KLA/ATP 1.18 1.24 1.27 1.00 .96 1.06 1.37
Nck1
KLA  ATP  ATP+KLA
 ENSMUST00000116522 ens|non-catalytic region of tyrosine kinase adaptor protein 1 [Source:RefSeq_peptide;Acc:NP_035008] [ENSMUST00000116522] KLA 1.59 1.56 1.35 1.27 1.34 1.04 1.21
ATP 1.25 1.32 1.00 1.18 1.79 1.25 .96
KLA/ATP 2.00 2.22 1.41 1.34 1.21 1.35 1.27
Nck1
KLA  ATP  ATP+KLA
 NM_010878 non-catalytic region of tyrosine kinase adaptor protein 1 (Nck1), mRNA [NM_010878] KLA 6.52 5.82 4.53 2.34 1.72 1.14 1.26
ATP .91 .92 1.07 .68 1.72 2.07 1.15
KLA/ATP 5.62 5.96 5.77 2.46 1.63 1.99 1.86
Nck2
KLA  ATP  ATP+KLA
 NM_010879 non-catalytic region of tyrosine kinase adaptor protein 2 (Nck2), mRNA [NM_010879] KLA 1.72 1.26 1.32 1.00 1.46 1.78 1.50
ATP 1.08 1.05 .84 .59 1.28 1.26 1.17
KLA/ATP 1.68 1.27 1.14 .80 .94 .99 1.91
Nfat5
KLA  ATP  ATP+KLA
 AK172011 activated spleen cDNA, RIKEN full-length enriched library, clone:F830029B05 product:nuclear factor of activated T-cells 5, full insert sequence. [AK172011] KLA .94 .90 .93 .93 1.28 1.27 1.16
ATP .95 .76 1.13 1.27 1.93 2.21 1.18
KLA/ATP .85 .84 1.10 .92 1.53 1.63 1.66
Nfat5
KLA  ATP  ATP+KLA
 NM_018823 nuclear factor of activated T-cells 5 (Nfat5), transcript variant b, mRNA [NM_018823] KLA .95 1.01 .99 1.03 1.08 1.13 1.19
ATP 1.05 1.22 1.67 1.98 1.74 1.38 1.17
KLA/ATP 1.03 1.07 1.34 1.38 1.30 1.19 1.40
Nfat5
KLA  ATP  ATP+KLA
 NM_133957 nuclear factor of activated T-cells 5 (Nfat5), transcript variant a, mRNA [NM_133957] KLA 1.07 1.07 1.00 .96 1.42 1.36 1.51
ATP 1.15 1.19 1.81 4.36 6.34 3.49 1.12
KLA/ATP 1.27 1.08 1.87 2.72 3.58 3.05 2.07
Nfatc1
KLA  ATP  ATP+KLA
 NM_016791 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1), transcript variant 1, mRNA [NM_016791] KLA .71 .66 .68 .62 .63 .67 .81
ATP 1.12 1.29 1.15 1.21 .83 .63 1.25
KLA/ATP .78 .79 .65 .74 .59 .45 .92
Nfatc1
KLA  ATP  ATP+KLA
 NM_198429 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1), transcript variant 2, mRNA [NM_198429] KLA .49 .41 .50 .43 .50 .78 .69
ATP 1.05 .81 .84 .54 .60 .38 .69
KLA/ATP .46 .37 .45 .32 .62 .39 .61
Nfatc2
KLA  ATP  ATP+KLA
 AK081853 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130082H17 product:nuclear factor of activated T-cells, cytoplasmic 2, full insert sequence. [AK081853] KLA .56 .52 .59 .61 .78 .78 .66
ATP 1.19 1.27 .67 .65 .62 .53 .79
KLA/ATP .52 .49 .71 .57 .65 .52 .53
Nfatc2
KLA  ATP  ATP+KLA
 NM_001037177 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 2, mRNA [NM_001037177] KLA .84 .79 .74 .82 .89 .98 .80
ATP 1.06 1.13 1.01 .87 .86 .83 1.10
KLA/ATP .76 .72 .89 .84 .84 .81 .84
Nfatc2
KLA  ATP  ATP+KLA
 NM_010899 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 1, mRNA [NM_010899] KLA .90 .91 .86 .91 .86 1.07 1.00
ATP 1.08 1.11 1.45 1.04 .88 .85 1.18
KLA/ATP .85 .89 .92 .89 .93 .84 1.13
Nfatc3
KLA  ATP  ATP+KLA
 AK084848 13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430001G08 product:nuclear factor of activated T-cells, cytoplasmic 3, full insert sequence. [AK084848] KLA 1.08 .96 .98 1.00 .98 1.03 .98
ATP 1.00 1.03 .93 .92 .92 1.11 .98
KLA/ATP 1.01 .87 1.10 .97 .96 .96 .99
Nfatc3
KLA  ATP  ATP+KLA
 NM_010901 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Nfatc3), mRNA [NM_010901] KLA .77 .68 .67 .77 .85 .90 1.04
ATP 1.01 .95 .89 .70 .70 .92 .98
KLA/ATP .77 .66 .64 .59 .82 .90 .90
Nfatc4
KLA  ATP  ATP+KLA
 AK014164 13 days embryo head cDNA, RIKEN full-length enriched library, clone:3110041H08 product:nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4, full insert sequence. [AK014164] KLA .90 .92 .91 1.00 .99 .98 .95
ATP .90 1.03 .96 .98 .95 .97 1.00
KLA/ATP .95 .87 1.00 .98 .96 .96 .92
Nfatc4
KLA  ATP  ATP+KLA
 NM_023699 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 (Nfatc4), mRNA [NM_023699] KLA 1.28 1.38 1.44 1.58 1.40 1.41 1.46
ATP 1.03 1.06 1.23 1.24 1.32 1.40 1.41
KLA/ATP 1.30 1.38 1.47 1.28 1.38 1.40 1.63
Ngef
KLA  ATP  ATP+KLA
 NM_019867 neuronal guanine nucleotide exchange factor (Ngef), transcript variant 2, mRNA [NM_019867] KLA .98 1.01 .93 .94 1.00 .99 1.01
ATP .94 1.00 1.03 .96 1.00 .93 1.01
KLA/ATP 1.01 .94 1.02 .99 1.07 1.01 .93
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Nrp1
KLA  ATP  ATP+KLA
 AK040447 0 day neonate thymus cDNA, RIKEN full-length enriched library, clone:A430096P05 product:neuropilin, full insert sequence. [AK040447] KLA .33 .32 .34 .36 .34 .50 .45
ATP .92 .85 1.03 .87 .56 .82 .82
KLA/ATP .31 .33 .44 .37 .41 .56 .58
Nrp1
KLA  ATP  ATP+KLA
 NM_008737 neuropilin 1 (Nrp1), mRNA [NM_008737] KLA .53 .52 .45 .39 .25 .25 .25
ATP 1.14 1.11 .84 .98 .64 .66 .66
KLA/ATP .64 .54 .39 .48 .36 .40 .36
Ntn1
KLA  ATP  ATP+KLA
 NM_008744 netrin 1 (Ntn1), mRNA [NM_008744] KLA 1.05 1.05 1.03 1.10 1.11 1.09 1.08
ATP 1.02 1.07 1.00 .95 1.17 1.04 1.01
KLA/ATP 1.02 1.05 .95 .99 1.04 1.09 1.06
Ntn2l
KLA  ATP  ATP+KLA
 NM_010947 netrin 2-like (chicken) (Ntn2l), mRNA [NM_010947] KLA .73 .80 .68 .79 .94 .91 .95
ATP .94 .75 .63 1.17 1.33 1.10 1.22
KLA/ATP .71 .70 .63 .95 1.22 1.01 1.04
Ntn4
KLA  ATP  ATP+KLA
 NM_021320 netrin 4 (Ntn4), mRNA [NM_021320] KLA .98 .95 .98 1.00 1.00 1.02 .97
ATP .98 1.01 .98 .94 .99 1.07 .96
KLA/ATP .98 1.03 .98 1.00 .95 1.05 1.06
Ntng1
KLA  ATP  ATP+KLA
 AK048796 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230070N18 product:netrin G1, full insert sequence. [AK048796] KLA 1.04 1.00 1.00 .98 1.05 .93 .97
ATP .98 1.04 1.14 .97 .93 .93 1.01
KLA/ATP .92 .99 1.10 1.03 .99 .98 .96
Ntng1
KLA  ATP  ATP+KLA
 NM_030699 netrin G1 (Ntng1), mRNA [NM_030699] KLA .92 .93 1.01 1.01 1.05 1.01 .93
ATP 1.03 1.01 .96 1.00 .99 .97 .98
KLA/ATP .96 1.02 .97 1.03 1.01 .98 .98
Ntng2
KLA  ATP  ATP+KLA
 AK011411 10 days embryo whole body cDNA, RIKEN full-length enriched library, clone:2610016D08 product:unclassifiable, full insert sequence. [AK011411] KLA 1.05 .95 1.05 1.03 1.04 1.00 1.08
ATP .98 1.06 1.04 1.03 .98 .93 .97
KLA/ATP 1.07 1.13 1.11 1.01 .94 .97 1.08
Ntng2
KLA  ATP  ATP+KLA
 NM_133500 netrin G2 (Ntng2), transcript variant a, mRNA [NM_133500] KLA 1.09 1.03 1.08 1.08 1.11 1.09 1.06
ATP 1.00 1.01 1.05 .98 1.02 1.20 1.00
KLA/ATP 1.00 1.03 1.07 1.14 1.12 1.06 1.18
Pak1
KLA  ATP  ATP+KLA
 NM_011035 p21 (CDKN1A)-activated kinase 1 (Pak1), mRNA [NM_011035] KLA .72 .77 .79 .71 .67 .73 .95
ATP 1.10 1.07 .99 1.15 1.27 .62 .51
KLA/ATP .85 .83 .73 .76 .76 .55 .33
Pak2
KLA  ATP  ATP+KLA
 NM_177326 p21 (CDKN1A)-activated kinase 2 (Pak2), mRNA [NM_177326] KLA 1.23 1.24 1.26 1.17 1.19 1.09 1.13
ATP 1.04 1.01 .65 .58 .82 1.18 1.45
KLA/ATP 1.26 1.26 .78 .72 .71 .95 1.44
Pak3
KLA  ATP  ATP+KLA
 NM_008778 p21 (CDKN1A)-activated kinase 3 (Pak3), mRNA [NM_008778] KLA 1.06 1.02 1.03 1.00 1.06 1.01 1.01
ATP 1.05 1.01 1.03 .97 .98 1.08 1.07
KLA/ATP 1.00 .99 .99 1.03 1.00 1.01 1.08
Pak4
KLA  ATP  ATP+KLA
 NM_027470 p21 (CDKN1A)-activated kinase 4 (Pak4), mRNA [NM_027470] KLA 1.41 1.51 1.62 1.57 1.88 1.26 1.06
ATP 1.13 1.15 1.04 1.21 1.73 1.45 1.03
KLA/ATP 1.58 1.60 1.31 1.65 1.84 1.64 1.40
Pak6
KLA  ATP  ATP+KLA
 AK028788 10 days neonate skin cDNA, RIKEN full-length enriched library, clone:4732456M09 product:p21 (CDKN1A)-activated kinase 6, full insert sequence. [AK028788] KLA 1.38 1.33 1.40 1.45 1.42 1.49 1.20
ATP .95 .93 1.15 1.21 1.21 1.32 1.10
KLA/ATP 1.33 1.38 1.55 1.44 1.57 1.45 1.36
Pak7
KLA  ATP  ATP+KLA
 AK077967 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030481C12 product:hypothetical protein, full insert sequence. [AK077967] KLA 1.00 1.01 1.07 1.02 .99 1.01 1.05
ATP .93 .95 1.03 1.01 1.02 .92 1.00
KLA/ATP 1.04 1.01 .99 1.04 .99 1.06 1.02
Plxna1
KLA  ATP  ATP+KLA
 AK220460 mRNA for mKIAA4053 protein [AK220460] KLA .92 .92 .90 .74 1.07 1.06 1.70
ATP 1.11 1.22 .71 .91 1.67 1.55 2.00
KLA/ATP 1.05 .99 .53 .92 1.40 1.21 1.90
Plxna1
KLA  ATP  ATP+KLA
 NM_008881 plexin A1 (Plxna1), mRNA [NM_008881] KLA 1.42 1.25 1.16 1.24 1.52 1.21 1.25
ATP 1.53 1.77 2.79 3.10 1.38 1.05 1.65
KLA/ATP 1.76 1.77 2.27 2.27 1.48 1.20 2.07
Plxna2
KLA  ATP  ATP+KLA
 NM_008882 plexin A2 (Plxna2), mRNA [NM_008882] KLA .58 .46 .37 .32 .29 .46 1.07
ATP 1.05 .98 .93 .97 1.91 .83 1.60
KLA/ATP .54 .46 .43 .49 1.14 .71 1.09
Plxna3
KLA  ATP  ATP+KLA
 NM_008883 plexin A3 (Plxna3), mRNA [NM_008883] KLA .80 .82 .76 .75 .76 .74 .70
ATP 1.04 1.11 1.08 .94 .80 .72 .79
KLA/ATP .81 .78 .84 .73 .73 .63 .61
Plxna4
KLA  ATP  ATP+KLA
 NM_175750 plexin A4 (Plxna4), mRNA [NM_175750] KLA 1.04 1.03 1.17 1.03 .95 .95 .95
ATP 1.02 1.03 1.08 1.01 .95 1.04 1.71
KLA/ATP 1.06 1.01 1.07 1.00 1.02 .92 1.22
Plxnb1
KLA  ATP  ATP+KLA
 NM_172775 plexin B1 (Plxnb1), mRNA [NM_172775] KLA .95 .97 .98 .99 .95 .95 .91
ATP 1.03 .97 .95 .95 1.02 .94 .96
KLA/ATP 1.00 .99 .98 .99 .99 1.01 .96
Plxnb2
KLA  ATP  ATP+KLA
 XM_001003435 gb|PREDICTED: Mus musculus plexin B2, transcript variant 14 (Plxnb2), mRNA [XM_001003435] KLA .78 .77 .83 .76 .83 1.04 1.15
ATP 1.08 1.16 .87 .88 .69 .56 .95
KLA/ATP .92 .84 .63 .70 .55 .71 1.10
Plxnb3
KLA  ATP  ATP+KLA
 NM_019587 plexin B3 (Plxnb3), mRNA [NM_019587] KLA .85 .82 .91 .79 .81 1.70 2.89
ATP 1.09 1.04 2.62 1.06 .80 .52 1.27
KLA/ATP .81 .82 .94 .93 .83 .63 .97
Plxnc1
KLA  ATP  ATP+KLA
 NM_018797 plexin C1 (Plxnc1), mRNA [NM_018797] KLA .81 .75 .69 .54 .41 .24 .30
ATP 1.13 1.17 1.06 1.10 1.03 .53 .39
KLA/ATP .78 .83 .69 .69 .67 .52 .23
Ppp3ca
KLA  ATP  ATP+KLA
 NM_008913 protein phosphatase 3, catalytic subunit, alpha isoform (Ppp3ca), mRNA [NM_008913] KLA .76 .85 .81 .85 .73 .70 .52
ATP .96 .78 .55 .46 .31 .33 .48
KLA/ATP .74 .64 .52 .42 .37 .36 .45
Ppp3cb
KLA  ATP  ATP+KLA
 AK135203 12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720421K10 product:protein phosphatase 3, catalytic subunit, beta isoform, full insert sequence. [AK135203] KLA 1.74 1.57 1.91 1.59 1.47 1.26 1.40
ATP 1.17 1.03 1.30 1.00 .81 .62 1.37
KLA/ATP 1.68 1.70 1.91 1.37 1.09 .47 1.13
Ppp3cb
KLA  ATP  ATP+KLA
 AK171904 activated spleen cDNA, RIKEN full-length enriched library, clone:F830018L06 product:Protein phosphatase 3 catalytic subunit beta3 (EC 3.1.3.16) (Serine [AK171904] KLA 1.29 1.29 1.21 1.15 1.22 1.13 1.28
ATP .90 .86 .80 .98 .94 .73 .92
KLA/ATP 1.06 1.03 .77 1.04 .92 .68 .90
Ppp3cb
KLA  ATP  ATP+KLA
 NM_008914 protein phosphatase 3, catalytic subunit, beta isoform (Ppp3cb), mRNA [NM_008914] KLA 1.21 1.29 1.38 1.24 1.29 1.08 1.23
ATP 1.15 1.31 1.09 1.29 .86 .60 .64
KLA/ATP 1.33 1.40 1.04 1.28 .79 .58 .73
Ppp3cc
KLA  ATP  ATP+KLA
 AK037563 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026K22 product:unclassifiable, full insert sequence [AK037563] KLA 1.27 1.18 1.21 1.15 1.01 .92 1.36
ATP .96 1.09 1.10 1.03 .85 1.06 1.47
KLA/ATP 1.17 1.24 1.07 1.13 .91 .88 1.36
Ppp3cc
KLA  ATP  ATP+KLA
 NM_008915 protein phosphatase 3, catalytic subunit, gamma isoform (Ppp3cc), mRNA [NM_008915] KLA 1.64 1.81 1.79 1.35 .90 .70 1.31
ATP .90 .90 1.13 .93 .86 1.40 1.60
KLA/ATP 1.45 1.62 1.74 1.47 1.04 1.01 1.31
Ppp3r1
KLA  ATP  ATP+KLA
 NM_024459 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) (Ppp3r1), mRNA [NM_024459] KLA 1.02 1.17 .93 1.27 1.15 1.30 1.30
ATP .97 .95 .77 .91 .99 1.18 1.10
KLA/ATP 1.12 1.04 .88 1.00 1.10 1.10 1.07
Ppp3r2
KLA  ATP  ATP+KLA
 NM_001004025 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type II) (Ppp3r2), mRNA [NM_001004025] KLA 1.03 1.05 1.06 1.08 1.12 1.05 1.04
ATP 1.00 1.02 1.04 1.04 .99 .99 1.01
KLA/ATP 1.04 1.12 1.03 1.09 1.00 .99 1.00
Ptk2
KLA  ATP  ATP+KLA
 NM_007982 PTK2 protein tyrosine kinase 2 (Ptk2), mRNA [NM_007982] KLA .99 .99 1.02 1.04 1.09 1.22 1.57
ATP 1.04 1.09 .95 .98 .67 .96 .87
KLA/ATP .99 1.03 .87 .93 .81 1.16 1.04
Rac1
KLA  ATP  ATP+KLA
 NM_009007 RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] KLA 1.02 1.01 1.02 .99 1.03 1.15 1.08
ATP .99 1.15 1.01 1.27 1.06 1.20 1.06
KLA/ATP 1.00 1.04 .88 1.16 .91 1.21 1.38
Rac2
KLA  ATP  ATP+KLA
 NM_009008 RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] KLA 1.55 1.68 1.86 2.15 3.36 3.59 3.74
ATP 1.13 1.16 .74 .99 .84 .91 1.66
KLA/ATP 1.59 1.71 1.19 1.56 1.21 1.60 3.48
Rac3
KLA  ATP  ATP+KLA
 NM_133223 RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] KLA 2.03 2.20 2.64 2.18 2.95 2.29 1.41
ATP 1.02 1.12 .94 1.42 1.16 .84 .87
KLA/ATP 2.30 2.32 1.57 2.55 1.75 1.47 1.61
Rasa1
KLA  ATP  ATP+KLA
 AK042801 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730025L23 product:unclassifiable, full insert sequence. [AK042801] KLA .85 .88 .86 .82 .86 .85 .92
ATP 1.05 .95 .85 .80 .81 .82 .95
KLA/ATP .94 .88 .87 .85 .86 .83 .91
Rasa1
KLA  ATP  ATP+KLA
 NM_145452 RAS p21 protein activator 1 (Rasa1), mRNA [NM_145452] KLA .37 .38 .36 .36 .33 .35 .57
ATP .96 .88 .54 .42 .23 .23 .70
KLA/ATP .36 .35 .23 .25 .23 .23 .44
Rgs3
KLA  ATP  ATP+KLA
 NM_134257 regulator of G-protein signaling 3 (Rgs3), transcript variant 2, mRNA [NM_134257] KLA .95 .92 .95 1.26 1.43 1.46 1.39
ATP 1.03 1.10 1.16 1.25 .96 1.01 .79
KLA/ATP .94 .91 1.22 1.27 1.07 1.01 1.50
Rhoa
KLA  ATP  ATP+KLA
 NM_016802 ras homolog gene family, member A (Rhoa), mRNA [NM_016802] KLA .93 1.00 1.07 .97 1.08 1.06 1.02
ATP .93 .88 .49 .61 .63 .78 1.05
KLA/ATP .94 .92 .59 .63 .61 .78 1.12
Rhod
KLA  ATP  ATP+KLA
 NM_007485 ras homolog gene family, member D (Rhod), mRNA [NM_007485] KLA .54 .53 .50 .56 .54 .55 .48
ATP 1.08 1.13 1.07 1.09 .78 .65 1.50
KLA/ATP .55 .57 .59 .61 .64 .77 1.00
Rnd1
KLA  ATP  ATP+KLA
 BC048531 Rho family GTPase 1, mRNA (cDNA clone MGC:58446 IMAGE:6535763), complete cds. [BC048531] KLA 2.62 2.52 2.41 2.35 1.90 1.44 1.46
ATP .97 1.08 1.37 1.58 1.96 1.62 1.25
KLA/ATP 2.24 2.55 3.11 2.92 2.88 2.32 1.86
Rnd1
KLA  ATP  ATP+KLA
 NM_172612 Rho family GTPase 1 (Rnd1), mRNA [NM_172612] KLA 15.91 14.15 9.39 7.66 3.92 2.90 4.15
ATP .94 .96 1.64 3.30 7.01 5.36 1.69
KLA/ATP 15.79 16.19 16.75 14.49 12.67 11.04 6.99
Robo1
KLA  ATP  ATP+KLA
 AK040651 adult male aorta and vein cDNA, RIKEN full-length enriched library, clone:A530006L21 product:roundabout homolog 1 (Drosophila), full insert sequence. [AK040651] KLA .97 1.09 1.00 .98 1.03 .98 1.05
ATP 1.10 1.02 1.04 1.04 1.00 1.03 .98
KLA/ATP 1.01 .99 1.02 1.03 1.04 1.05 1.03
Robo1
KLA  ATP  ATP+KLA
 NM_019413 roundabout homolog 1 (Drosophila) (Robo1), mRNA [NM_019413] KLA .98 1.02 .99 1.01 1.03 1.04 1.02
ATP 1.00 1.03 1.01 1.01 1.04 1.00 1.00
KLA/ATP .99 1.06 .91 1.04 1.00 .98 1.01
Robo2
KLA  ATP  ATP+KLA
 AK031495 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030441B21 product:roundabout homolog 2 (Drosophila), full insert sequence. [AK031495] KLA .97 .96 1.11 .99 1.05 .97 1.10
ATP 1.05 .93 .97 1.04 .98 1.04 .99
KLA/ATP 1.05 .99 1.02 .95 .97 .95 .97
Robo2
KLA  ATP  ATP+KLA
 NM_175549 roundabout homolog 2 (Drosophila) (Robo2), mRNA [NM_175549] KLA 1.01 .98 .99 1.02 1.01 1.10 1.04
ATP .98 .98 1.03 1.03 1.02 1.00 1.04
KLA/ATP 1.01 1.01 .98 .99 1.00 1.03 1.02
Rock1
KLA  ATP  ATP+KLA
 NM_009071 Rho-associated coiled-coil containing protein kinase 1 (Rock1), mRNA [NM_009071] KLA 2.40 2.48 2.37 3.07 1.94 1.42 1.21
ATP .95 .92 .87 .70 1.13 1.74 .98
KLA/ATP 2.27 2.35 2.56 1.60 1.65 1.56 1.23
Rock2
KLA  ATP  ATP+KLA
 NM_009072 Rho-associated coiled-coil containing protein kinase 2 (Rock2), mRNA [NM_009072] KLA .99 .92 .83 .87 .73 .74 1.04
ATP 1.07 1.31 1.16 1.02 1.02 1.03 .88
KLA/ATP 1.00 1.07 .93 .85 .69 .63 .81
Sema3a
KLA  ATP  ATP+KLA
 AK053115 0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030004A12 product:sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A, full insert sequence. [AK053115] KLA .99 1.06 1.07 1.00 1.00 1.02 .92
ATP .99 1.01 1.05 .93 .95 1.01 .98
KLA/ATP .98 .96 1.10 .99 1.01 .98 .98
Sema3a
KLA  ATP  ATP+KLA
 NM_009152 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A (Sema3a), mRNA [NM_009152] KLA .98 1.02 1.04 .99 1.00 1.00 1.05
ATP .96 1.01 1.01 .92 1.01 .97 1.01
KLA/ATP 1.00 1.05 1.00 1.03 1.03 1.04 1.01
Sema3b
KLA  ATP  ATP+KLA
 NM_001042779 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B (Sema3b), transcript variant 1, mRNA [NM_001042779] KLA 1.07 1.06 .94 1.00 1.02 1.05 1.02
ATP 1.01 1.00 1.05 1.19 1.13 1.11 1.08
KLA/ATP 1.03 1.02 1.01 1.04 1.06 1.14 1.06
Sema3c
KLA  ATP  ATP+KLA
 AK078589 11 days embryo gonad cDNA, RIKEN full-length enriched library, clone:7030412F17 product:sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C, full insert sequence. [AK078589] KLA .93 .97 .94 .89 .93 .99 1.04
ATP 1.03 1.00 .94 1.09 1.65 1.53 1.16
KLA/ATP 1.02 1.01 .96 .95 1.07 1.04 1.15
Sema3d
KLA  ATP  ATP+KLA
 NM_028882 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D (Sema3d), mRNA [NM_028882] KLA 1.07 1.10 .96 1.01 1.04 .98 .96
ATP 1.02 1.09 .91 .98 .97 1.04 1.00
KLA/ATP 1.00 1.00 1.04 .98 .96 .94 1.06
Sema3e
KLA  ATP  ATP+KLA
 AK049580 7 days embryo whole body cDNA, RIKEN full-length enriched library, clone:C430045N03 product:unclassifiable, full insert sequence. [AK049580] KLA 1.01 1.03 1.07 .98 .98 1.03 1.08
ATP .99 1.07 1.03 .96 1.04 .90 .96
KLA/ATP .91 1.02 .99 .97 1.01 1.04 .98
Sema3e
KLA  ATP  ATP+KLA
 NM_011348 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E (Sema3e), mRNA [NM_011348] KLA .99 .96 1.01 1.00 1.02 1.01 .97
ATP .97 1.04 1.01 .95 .97 1.02 .96
KLA/ATP 1.03 1.05 1.01 .98 .96 .98 .99
Sema3f
KLA  ATP  ATP+KLA
 NM_011349 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F (Sema3f), mRNA [NM_011349] KLA 1.14 1.12 1.09 1.04 1.06 .99 .93
ATP .97 1.00 1.08 1.01 1.00 .97 .90
KLA/ATP 1.13 1.11 1.06 1.01 1.00 .92 .95
Sema3g
KLA  ATP  ATP+KLA
 AK129018 cDNA fis, clone TRACH3033868, highly similar to Homo sapiens semaphorin sem2 [AK129018] KLA 1.02 1.04 1.06 1.05 1.10 1.26 1.31
ATP 1.00 .87 .98 .91 1.06 1.05 1.26
KLA/ATP 1.01 1.07 1.12 .96 1.02 1.05 1.26
Sema4a
KLA  ATP  ATP+KLA
 NM_013658 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4A (Sema4a), mRNA [NM_013658] KLA 6.23 6.35 6.93 6.49 6.41 4.55 1.68
ATP 1.08 1.08 1.08 2.07 1.48 2.58 4.23
KLA/ATP 6.34 7.08 6.63 6.96 4.79 3.86 7.40
Sema4b
KLA  ATP  ATP+KLA
 NM_013659 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4B (Sema4b), mRNA [NM_013659] KLA 1.02 .92 .93 .94 .84 .97 1.09
ATP 1.01 1.02 .91 .93 1.25 1.31 1.06
KLA/ATP .94 1.04 .99 .88 1.04 1.27 .95
Sema4c
KLA  ATP  ATP+KLA
 NM_001126047 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4C (Sema4c), mRNA [NM_001126047] KLA 4.44 4.46 5.66 6.56 6.64 4.36 3.23
ATP 1.05 .99 .97 1.02 1.44 1.64 1.24
KLA/ATP 4.66 4.89 4.24 3.44 3.90 2.65 1.59
Sema4d
KLA  ATP  ATP+KLA
 NM_013660 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D (Sema4d), mRNA [NM_013660] KLA 1.80 1.92 2.11 1.80 2.36 1.96 2.38
ATP 1.17 1.44 .73 1.75 1.66 .89 2.28
KLA/ATP 2.23 2.36 .95 2.06 1.26 1.88 4.50
Sema4f
KLA  ATP  ATP+KLA
 NM_011350 sema domain, immunoglobulin domain (Ig), TM domain, and short cytoplasmic domain (Sema4f), transcript variant 1, mRNA [NM_011350] KLA .98 1.08 1.07 1.04 1.12 1.12 1.07
ATP 1.01 1.00 1.03 1.09 1.01 1.01 1.05
KLA/ATP 1.02 1.01 1.09 1.07 1.03 1.08 1.16
Sema4g
KLA  ATP  ATP+KLA
 NM_011976 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4G (Sema4g), mRNA [NM_011976] KLA 1.00 .93 1.08 1.00 .98 1.00 1.12
ATP .97 .99 .94 .97 1.00 1.01 .95
KLA/ATP 1.01 1.06 .98 .97 1.04 1.12 .95
Sema5a
KLA  ATP  ATP+KLA
 NM_009154 sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A (Sema5a), mRNA [NM_009154] KLA 1.04 .96 1.00 1.05 .99 .98 .99
ATP 1.01 1.02 .99 .98 .89 1.02 .97
KLA/ATP 1.00 1.02 1.06 1.00 .96 .99 1.04
Sema5b
KLA  ATP  ATP+KLA
 NM_013661 sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B (Sema5b), mRNA [NM_013661] KLA 1.07 1.09 1.04 1.09 1.10 1.10 1.03
ATP 1.03 1.01 1.05 1.04 1.05 1.05 1.00
KLA/ATP 1.04 1.08 1.15 1.10 1.07 1.13 1.19
Sema6a
KLA  ATP  ATP+KLA
 NM_018744 sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A (Sema6a), mRNA [NM_018744] KLA 1.07 1.04 1.03 1.06 1.00 1.08 1.05
ATP .93 .96 1.05 1.13 1.14 1.12 1.15
KLA/ATP .98 1.07 .99 1.06 1.12 1.07 1.10
Sema6b
KLA  ATP  ATP+KLA
 NM_013662 sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B (Sema6b), mRNA [NM_013662] KLA .47 .52 .48 .50 .57 .54 .55
ATP 1.07 1.10 .77 .78 .55 .65 .71
KLA/ATP .57 .58 .56 .56 .51 .52 .40
Sema6c
KLA  ATP  ATP+KLA
 NM_011351 sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6C (Sema6c), mRNA [NM_011351] KLA 1.24 1.12 1.18 1.15 1.19 1.32 1.07
ATP 1.09 1.08 1.29 1.26 1.34 1.41 1.12
KLA/ATP 1.15 1.26 1.53 1.44 1.47 1.49 1.32
Sema6d
KLA  ATP  ATP+KLA
 NM_172537 sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D (Sema6d), transcript variant 1, mRNA [NM_172537] KLA .79 .74 .81 .85 .73 .57 .33
ATP 1.02 .97 .77 .95 1.08 .81 .36
KLA/ATP .82 .79 .76 .96 .88 .63 .34
Sema6d
KLA  ATP  ATP+KLA
 NM_199241 sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D (Sema6d), transcript variant 4, mRNA [NM_199241] KLA .97 1.04 1.00 1.03 .91 .99 .96
ATP .97 1.07 .96 .95 .97 1.00 1.00
KLA/ATP .98 .93 .94 1.01 .95 1.01 .92
Sema7a
KLA  ATP  ATP+KLA
 NM_011352 sema domain, immunoglobulin domain (Ig), and GPI membrane anchor, (semaphorin) 7A (Sema7a), mRNA [NM_011352] KLA 2.21 2.24 2.95 2.99 2.43 2.03 1.47
ATP .98 1.04 1.41 1.55 1.53 1.79 1.41
KLA/ATP 2.25 2.91 3.15 3.39 2.71 3.51 3.38
Slit1
KLA  ATP  ATP+KLA
 NM_015748 slit homolog 1 (Drosophila) (Slit1), mRNA [NM_015748] KLA 1.19 1.18 1.23 1.29 1.14 1.36 1.20
ATP 1.01 1.04 1.22 1.33 1.35 1.20 1.08
KLA/ATP 1.17 1.21 1.35 1.37 1.35 1.38 1.20
Slit2
KLA  ATP  ATP+KLA
 AK038807 adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230065A06 product:unclassifiable, full insert sequence. [AK038807] KLA 1.01 .99 1.02 1.00 .94 .97 .95
ATP 1.03 1.05 .99 .94 .96 .94 1.03
KLA/ATP .93 .96 .96 .89 .95 .99 1.03
Slit2
KLA  ATP  ATP+KLA
 NM_178804 slit homolog 2 (Drosophila) (Slit2), mRNA [NM_178804] KLA .97 1.02 .99 .99 .99 1.00 1.00
ATP .97 1.01 1.05 .92 1.02 .93 1.00
KLA/ATP .93 .99 1.01 .99 .98 1.02 1.06
Slit3
KLA  ATP  ATP+KLA
 NM_011412 slit homolog 3 (Drosophila) (Slit3), mRNA [NM_011412] KLA 1.03 1.02 .94 .98 1.02 1.01 .96
ATP .97 .95 .99 .94 1.04 1.06 1.05
KLA/ATP 1.00 .91 .98 .93 1.01 .95 1.06
Srgap1
KLA  ATP  ATP+KLA
 AK047250 10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930042C02 product:unclassifiable, full insert sequence. [AK047250] KLA .98 1.05 .97 1.00 .98 .95 1.05
ATP 1.02 .97 .99 .98 1.01 .92 1.02
KLA/ATP 1.05 1.03 .98 .98 1.04 1.01 1.08
Srgap2
KLA  ATP  ATP+KLA
 AK143649 6 days neonate spleen cDNA, RIKEN full-length enriched library, clone:F430006B14 product:Hypothetical cell division control protein 15, full insert sequence. [AK143649] KLA 1.13 1.11 1.06 1.13 1.11 1.03 1.01
ATP 1.01 1.07 1.11 1.04 .90 .93 1.16
KLA/ATP 1.11 1.20 1.17 .98 .96 .95 .96
Srgap2
KLA  ATP  ATP+KLA
 NM_001081011 SLIT-ROBO Rho GTPase activating protein 2 (Srgap2), mRNA [NM_001081011] KLA 1.74 1.91 2.05 1.99 2.12 1.98 1.30
ATP 1.02 .99 .99 1.12 .62 .67 .96
KLA/ATP 1.79 1.84 1.81 1.87 .95 .68 1.44
Srgap3
KLA  ATP  ATP+KLA
 NM_080448 SLIT-ROBO Rho GTPase activating protein 3 (Srgap3), mRNA [NM_080448] KLA .71 .66 .63 .63 .62 .68 .61
ATP 1.01 1.04 1.04 1.31 .88 .69 .63
KLA/ATP .69 .71 .78 .71 .63 .64 .73
Unc5a
KLA  ATP  ATP+KLA
 NM_153131 unc-5 homolog A (C. elegans) (Unc5a), mRNA [NM_153131] KLA .77 .74 .72 .67 .50 .37 .18
ATP 1.06 1.07 1.17 1.15 .75 .38 .17
KLA/ATP .81 .72 .81 .81 .61 .43 .20
Unc5b
KLA  ATP  ATP+KLA
 NM_029770 unc-5 homolog B (C. elegans) (Unc5b), mRNA [NM_029770] KLA 1.42 1.47 1.31 .98 .71 1.02 1.20
ATP .91 .92 1.04 1.53 2.74 4.13 1.53
KLA/ATP 1.35 1.53 1.55 1.59 5.01 5.69 2.03
Unc5c
KLA  ATP  ATP+KLA
 AK034558 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430006E08 product:unc5 homolog (C. elegans) 3, full insert sequence. [AK034558] KLA 1.02 .99 1.06 .98 .91 1.00 1.00
ATP .96 .98 1.08 1.04 .93 .94 .95
KLA/ATP .95 1.04 .95 1.04 .97 .94 .91
Unc5c
KLA  ATP  ATP+KLA
 NM_009472 unc-5 homolog C (C. elegans) (Unc5c), mRNA [NM_009472] KLA 1.02 .98 .99 .94 .97 1.04 1.02
ATP .96 1.01 1.00 .95 .95 .97 .99
KLA/ATP 1.02 1.00 1.00 .97 .94 .97 .96
Unc5d
KLA  ATP  ATP+KLA
 NM_153135 unc-5 homolog D (C. elegans) (Unc5d), mRNA [NM_153135] KLA 1.03 1.00 1.01 .96 .99 .99 1.02
ATP 1.01 .98 1.22 .99 .97 1.01 .98
KLA/ATP 1.03 .99 1.02 .98 .98 .98 1.05